Pharmacy Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma
Antigenics, 05/01/09

Antigenics Inc. announced that Oncophage has been granted orphan drug status for the treatment of glioma by the US Food and Drug Administration. In March, the European Medicines Agency granted a similar designation for Oncophage. "Glioma is such an aggressive and challenging cancer that when patients are diagnosed with recurrence of this life threatening disease, they rarely live beyond six months," said Andrew T. Parsa, MD, PhD, associate professor in the department of neurological surgery at the University of California, San Francisco, and lead investigator of a Phase 2 trial evaluating Oncophage in glioma. "Given the poor survival rates, the medical community needs new treatment options, and I am hopeful of the potential for Oncophage to significantly improve clinical outcomes in this patient population."

<< Previous
Meds mobilized for swine flu outbreak

Next >>
Outcome of new Mirapexin/ Sifrol (pramipexole) study set to...